Roxane HIV-Pain Scholars at Hopkins

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

COLUMBUS, Ohio--Roxane Laboratories has announced that Johns Hopkins University School of Medicine will implement the Roxane HIV-Pain Scholars program to train physicians, nurses, and pharmacists to treat and manage HIV-related peripheral nerve pain.

COLUMBUS, Ohio--Roxane Laboratories has announced that Johns HopkinsUniversity School of Medicine will implement the Roxane HIV-PainScholars program to train physicians, nurses, and pharmaciststo treat and manage HIV-related peripheral nerve pain.

"The treatment of pain is important to patients with HIV-relateddisease," said Justin McArthur, MB, MPH, of Johns HopkinsDepartment of Neurology and director of the scholarship program."Many health care providers do not know which therapies touse or how best to use them, and some patients suffer unnecessarily.The Johns Hopkins program will provide practical information formedical professionals specializing in HIV patient care."

Six scholars will be selected by Johns Hopkins each year to accompanyDr. McArthur for 4 days to observe patient evaluations in a multidisciplinaryAIDS treatment clinic, a research clinic, and a chronic care AIDSfacility. Program participants will also receive individualizedtutorials in managing nerve pain, a common symptom of HIV infection.

"This is a hands-on program; participants will see the patientsand the benefits of adequate peripheral nerve pain managementfirsthand," Dr. McArthur said. "We hope participantswill return to their institutions and share the information they'vereceived, improving overall HIV pain management."

Physicians, nurses, and pharmacists wishing to apply to the JohnsHopkins program should write to Dr. McArthur at the Departmentof Neurology, Johns Hopkins University, 600 Wolfe Street, Meyer6-109, Baltimore, MD 21205, or telephone him at 410-955-3730.

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Related Content